Mode
Text Size
Log in / Sign up

Myasthenia Gravis

Subtypes of Myasthenia Gravis

Generalized myasthenia gravis 6

13 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Myasthenia Gravis

13 trials tracked for Myasthenia Gravis: 2 in phase 3 or 4 and 1 with published results. The most-cited published study has 900 citations.

13Trials tracked
2Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 2 Phase 2 8 Other / NA 3
  1. Phase 3 Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy Completed · 900 cited
  2. Phase 3 A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG) Completed
  3. Phase 2 Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis Completed
  4. Phase 2 Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis Completed
  5. Phase 2 A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness Completed
  6. Phase 2 Efficacy of Methotrexate in Myasthenia Gravis Completed
Show 7 more trials
  1. Phase 2 A Study of RVT-1401 in Myasthenia Gravis (MG) Patients Completed
  2. Phase 2 A Study of TAK-079 in People With Generalized Myasthenia Gravis Completed
  3. Phase 2 BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis Completed
  4. Phase 2 Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis Completed
  5. N/A Clinical Trial Comparing Two Non-Surgical Treatments for Severe Blepharoptosis Completed
  6. N/A Acupuncture in Myasthenia Gravis (AcuMG) Completed
  7. N/A Clinical Trial to Improve the Magnetic Levator Prosthesis Completed

Showing the 13 most-cited and recently-updated of 13 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Questions about Myasthenia Gravis

Which specific antibodies must be present for Epysqli approval in myasthenia gravis?

Epysqli (eculizumab-sbja) is FDA-approved for generalized myasthenia gravis only in adult patients who test positive for anti-acetylcholine receptor (AChR) antibodies.

Full answer →
Can thymoma be associated with myasthenia gravis and stiff person syndrome?

Yes, thymoma can be associated with both myasthenia gravis and stiff person syndrome, though this combination is very rare.

Full answer →
Do complement inhibitors improve outcomes for myasthenia gravis patients?

Yes, complement inhibitors (eculizumab, ravulizumab, zilucoplan) significantly improve symptoms and daily functioning in AChR antibody-positive generalized myasthenia gravis, based on multiple trials and real-world studies.

Full answer →
Is there a link between myasthenia gravis and the risk of autoimmune encephalitis?

Yes, people with myasthenia gravis have an increased risk of developing autoimmune encephalitis, likely due to shared autoimmune mechanisms and overlapping antibody targets.

Full answer →
Can a ketogenic diet improve quality of life for myasthenia gravis adults?

Early research suggests a ketogenic diet may improve symptoms and quality of life in myasthenia gravis, but evidence is limited to one small pilot study.

Full answer →
Does efgartigimod help improve symptoms for myasthenia gravis patients?

Yes, efgartigimod helps improve symptoms in myasthenia gravis patients, with most studies showing clinically meaningful improvements in daily living scores and muscle strength.

Full answer →
See all 6 questions about Myasthenia Gravis →

All Myasthenia Gravis Articles